Capstone Investment Advisors LLC bought a new position in Qiagen (NYSE:QGEN – Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 8,696 shares of the company’s stock, valued at approximately $395,000.
Several other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in shares of Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after purchasing an additional 500 shares during the period. Toronto Dominion Bank bought a new position in Qiagen in the 2nd quarter worth about $27,000. Massmutual Trust Co. FSB ADV raised its holdings in shares of Qiagen by 39.8% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after acquiring an additional 243 shares in the last quarter. CWM LLC boosted its position in shares of Qiagen by 12.0% during the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after acquiring an additional 269 shares during the last quarter. Finally, Headlands Technologies LLC grew its holdings in shares of Qiagen by 396.6% during the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after purchasing an additional 2,189 shares in the last quarter. 70.00% of the stock is owned by institutional investors.
Qiagen Stock Performance
NYSE QGEN opened at $43.43 on Friday. The company has a 50-day simple moving average of $43.25 and a two-hundred day simple moving average of $43.73. Qiagen has a 12-month low of $39.03 and a 12-month high of $47.44. The firm has a market cap of $9.91 billion, a price-to-earnings ratio of 111.36, a PEG ratio of 3.39 and a beta of 0.41. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on Qiagen
Qiagen Profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
See Also
- Five stocks we like better than Qiagen
- 3 Healthcare Dividend Stocks to Buy
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- 3 Warren Buffett Stocks to Buy Now
- 3 Penny Stocks Ready to Break Out in 2025
- Investing In Automotive Stocks
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen (NYSE:QGEN – Free Report).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.